List of works - Alessandra Larocca

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

scientific article

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.

scientific article published on 15 December 2004

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

scientific article

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

scientific article published on 11 August 2011

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

scientific article

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

scientific article published on 05 February 2014

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

scientific article published on 18 May 2020

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

scientific article published on 12 October 2010

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

scientific article

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

scientific article published on 12 January 2011

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

scientific article

Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.

scientific article published on October 2012

Defibrotide: a review on clinical use and future development

scientific article published in August 2008

Early Relapse Risk in Newly Diagnosed Multiple Myeloma Patients Characterized by Next-Generation Sequencing

scientific article published on 02 July 2020

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

scientific article published on 31 August 2010

European Myeloma Network guidelines for the management of multiple myeloma-related complications

scientific article

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

scientific article published on February 2014

Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients

scientific article published on 06 May 2018

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

scientific article

How I treat fragile myeloma patients.

scientific article published on 31 August 2015

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

scientific article

Lenalidomide and its role in the management of multiple myeloma

scientific article published on June 2008

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

scientific article published on 8 April 2010

Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients

scientific article published on 21 September 2012

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

scientific article published on 23 January 2014

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results

scientific article

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

scientific article

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

scientific article published on 29 December 2011

Nuances in the Management of Older People With Multiple Myeloma

scientific article published on 2 April 2016

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data

scientific article

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

scientific article

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp

scientific article published on 17 April 2015

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

scientific article published in 2022

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

scientific article

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens

scientific article published on 18 November 2010

The impact of response on bone-directed therapy in patients with multiple myeloma.

scientific article published on 23 August 2013

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

scientific article published on January 2016

List of works by Alessandra Larocca

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.

Defibrotide: a review on clinical use and future development

Early Relapse Risk in Newly Diagnosed Multiple Myeloma Patients Characterized by Next-Generation Sequencing

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

European Myeloma Network guidelines for the management of multiple myeloma-related complications

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

How I treat fragile myeloma patients.

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

Lenalidomide and its role in the management of multiple myeloma

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

Nuances in the Management of Older People With Multiple Myeloma

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens

The impact of response on bone-directed therapy in patients with multiple myeloma.

Treatment of Newly Diagnosed Elderly Multiple Myeloma.